Multicenter, Safety and Efficacy, Open-Label Extension Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Thyroid Eye Disease
Phase of Trial: Phase III
Latest Information Update: 11 Mar 2019
Price : $35 *
At a glance
- Drugs Teprotumumab (Primary)
- Indications Graves ophthalmopathy
- Focus Therapeutic Use
- Acronyms OPTIC-X
- Sponsors Horizon Pharma USA
- 06 Mar 2019 Planned End Date changed from 1 Mar 2021 to 1 Mar 2022.
- 14 May 2018 Status changed from not yet recruiting to recruiting.
- 12 Mar 2018 New trial record